Cumberland Pharmaceuticals INC Form 4 insider transactions

Martin S. Brown Jr., a director at Cumberland Pharmaceuticals, amended a previous SEC filing to correct the number of shares acquired on March 25, 2024.

Joseph C. Galante, a director at Cumberland Pharmaceuticals, amends his previous SEC filing to correct the number of shares acquired on March 25, 2024.

A director of Cumberland Pharmaceuticals, James Jones, amended a previous filing to correct the number of shares acquired on March 25, 2024, increasing the reported amount from 1,000 to 2,500.

A Cumberland Pharmaceuticals director amended a previous filing to correct the number of shares acquired, increasing the reported amount by 1,500 shares.

Caroline Young, a director at Cumberland Pharmaceuticals, amends a previous SEC filing to correct the number of shares acquired on March 25, 2024.

Director Caroline Young of Cumberland Pharmaceuticals has acquired additional shares of common stock through a pre-arranged 10b5-1 trading plan.

Director James Jones of Cumberland Pharmaceuticals has acquired shares through a pre-arranged trading plan, increasing his holdings.

Cumberland Pharmaceuticals CEO A.J. Kazimi acquired shares of company stock through a pre-arranged trading plan between December 2nd and December 20th, 2024.

Director Kenneth Krogulski of Cumberland Pharmaceuticals has been steadily increasing his holdings of company stock through a pre-arranged trading plan.

Caroline Young, a director at Cumberland Pharmaceuticals, has been steadily increasing her holdings of company stock through a pre-arranged trading plan.

Director James Jones of Cumberland Pharmaceuticals has been steadily increasing his holdings of company stock through a pre-arranged trading plan.

Cumberland Pharmaceuticals' CEO, A.J. Kazimi, has been actively purchasing company stock through a pre-arranged trading plan.

Director Kenneth Krogulski of Cumberland Pharmaceuticals has been steadily increasing his holdings of company stock through a pre-arranged trading plan.

Director Caroline Young has been consistently purchasing Cumberland Pharmaceuticals (CPIX) common stock through a pre-arranged 10b5-1 trading plan.

Director James Jones of Cumberland Pharmaceuticals has been consistently purchasing company stock through a pre-arranged 10b5-1 trading plan.

Cumberland Pharmaceuticals' Chairman and CEO, A.J. Kazimi, has been consistently acquiring shares of the company's common stock through a pre-arranged 10b5-1 trading plan.

Director Kenneth Krogulski of Cumberland Pharmaceuticals incrementally increased his holdings of common stock through a pre-arranged 10b5-1 trading plan.

Director Caroline Young of Cumberland Pharmaceuticals incrementally increased her holdings of common stock through a pre-arranged 10b5-1 trading plan.

Director James Jones of Cumberland Pharmaceuticals incrementally increased his holdings of common stock through a pre-arranged 10b5-1 trading plan.

Cumberland Pharmaceuticals' Chairman and CEO, A.J. Kazimi, has been consistently acquiring shares of the company's common stock through a pre-arranged 10b5-1 trading plan.

Director Kenneth Krogulski of Cumberland Pharmaceuticals incrementally increased his holdings of common stock through a pre-arranged 10b5-1 trading plan.

Director Caroline Young of Cumberland Pharmaceuticals increased her holdings through a pre-arranged 10b5-1 trading plan, acquiring shares at prices ranging from $1.35 to $1.50.

Director Caroline Young of Cumberland Pharmaceuticals increased her holdings through a pre-arranged 10b5-1 trading plan, acquiring shares at prices ranging from $1.35 to $1.50.

Director Kenneth Krogulski of Cumberland Pharmaceuticals incrementally increased his holdings of common stock through a pre-arranged 10b5-1 trading plan.

Director James Jones of Cumberland Pharmaceuticals reported a series of open market purchases of common stock between August 1, 2024, and August 30, 2024, executed under a pre-arranged Rule 10b5-1 trading plan.

Cumberland Pharmaceuticals' Chairman and CEO, A.J. Kazimi, has been consistently purchasing small amounts of company stock through a pre-arranged 10b5-1 trading plan.

Director Kenneth Krogulski reports a series of common stock acquisitions through a pre-arranged 10b5-1 trading plan.

A.J. Kazimi, CEO of Cumberland Pharmaceuticals, reports ongoing purchases of common stock under a pre-arranged 10b5-1 trading plan.

Director James Jones of Cumberland Pharmaceuticals incrementally increased his holdings of common stock through a pre-arranged 10b5-1 trading plan.

Director Caroline Young of Cumberland Pharmaceuticals reported a series of open market purchases of common stock between July 1, 2024, and July 31, 2024, executed under a pre-arranged 10b5-1 trading plan.